Accessibility Menu
 
Tango Therapeutics logo

Tango Therapeutics

(NASDAQ) TNGX

Current Price$19.26
Market Cap$2.75B
Since IPO (2020)+88%
5 Year+87%
1 Year+1,096%
1 Month+52%

Tango Therapeutics Financials at a Glance

Market Cap

$2.75B

Revenue (TTM)

$62.38M

Net Income (TTM)

$101.59M

EPS (TTM)

$-0.86

P/E Ratio

-22.28

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$19.26

Volume

48,563

Open

$19.99

Previous Close

$19.26

Daily Range

$18.98 - $20.15

52-Week Range

$1.03 - $21.82

TNGX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tango Therapeutics

Industry

Biotechnology

Employees

137

CEO

Barbara L. Weber, MD

Headquarters

Boston, MA 02142, US

TNGX Financials

Key Financial Metrics (TTM)

Gross Margin

97%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-37%

Return on Capital

-30%

Return on Assets

-25%

Earnings Yield

-4.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.75B

Shares Outstanding

142.69M

Volume

48.56K

Short Interest

0.00%

Avg. Volume

3.45M

Financials (TTM)

Gross Profit

$60.10M

Operating Income

$111.29M

EBITDA

$109.01M

Operating Cash Flow

$138.89M

Capital Expenditure

$1.05M

Free Cash Flow

$139.93M

Cash & ST Invst.

$343.14M

Total Debt

$33.57M

Tango Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$479.00K

-111.6%

Gross Margin

0.00%

N/A

Market Cap

$2.75B

N/A

Market Cap/Employee

$17.73M

N/A

Employees

155

N/A

Net Income

$38.75M

-2.9%

EBITDA

$41.38M

-2.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$309.57M

+39.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$30.83M

-9.4%

Short Term Debt

$2.74M

+11.6%

Return on Assets

-25.48%

N/A

Return on Invested Capital

-29.52%

N/A

Free Cash Flow

$29.94M

+18.6%

Operating Cash Flow

$29.72M

+18.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KODKodiak Sciences Inc.
$37.00-6.94%
NRIXNurix Therapeutics, Inc.
$14.76-4.96%
SEPNSepterna, Inc.
$23.87-3.52%
EYPTEyePoint Pharmaceuticals, Inc.
$12.50-4.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About TNGX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.